Italy's PharmaNutra Q1 revenue jumps, helped by US unit strength


Overview

  • Italy mineral supplements maker's Q1 revenue rose 24.5% yr/yr, driven by domestic and foreign markets

  • Q1 net result increased 41.9% yr/yr


Outlook

  • Company did not provide specific guidance for current or future quarters in the press release


Result Drivers

  • NEW BUSINESS UNITS - Co said new business units, especially PharmaNutra USA, drove significant revenue growth

  • COMMERCIAL STRUCTURE - Co attributed revenue increase in domestic market to new commercial structure started in Jan 2026

  • FOREIGN MARKETS - Co said foreign market revenues rose 41.5%, with Europe, China and US contributing to growth


Company press release: ID:nBIA85vgNL


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q1 Revenue

EUR 33.4 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the pharmaceuticals peer group is "buy"

  • Wall Street's median 12-month price target for Pharmanutra SpA is €87.00, about 12.1% above its May 8 closing price of €77.60

  • The stock recently traded at 28 times the next 12-month earnings vs. a P/E of 25 three months ago


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.